Position of an international panel of lung cancer experts on the decision for expansion of approval for pembrolizumab in advanced non-small-cell lung cancer with a PD-L1 expression level of ≥1% by the USA Food and Drug Administration
Journal article published in 2019 by
G. Mountzios 
,
J. Remon,
S. Novello,
N. Blais,
R. Califano,
T. Cufer,
A. M. Dingemans,
S. V. Liu,
N. Peled,
N. A. Pennell,
M. Reck,
C. Rolfo,
D. Tan,
J. Vansteenkiste ,
H. West
and other authors.
,
J. Remon,
S. Novello,
N. Blais,
R. Califano,
T. Cufer,
A. M. Dingemans,
S. V. Liu,
N. Peled,
N. A. Pennell,
M. Reck,
C. Rolfo,
D. Tan,
J. Vansteenkiste ,
H. West
and other authors.
This paper was not found in any repository, but could be made available legally by the author.
Full text: Unavailable
Published version:
archiving forbidden
Data provided by 